UNSPSC 51342602: Fomivirsen

This classification denotes an antisense agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Z6W3S36X5. European Medicines Agency schedules Fomivirsen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02253MIG. Fomivirsen sodium generally arises in the molecular formula C204H243N63O114P20S20.20NA. The term FOMIVIRSEN SODIUM is a United States Adopted Name designation. Most nations schedule fomivirsen under HS 29349990 and SITC 51579.

As of Q4 2014, FOMIVIRSEN remains the US FDA Preferred Term for this commodity.

UNSPSC 51342602 Fomivirsen is a Commodity code that nominally covers an antiviral pharmaceutical, but recent state and local solicitations show little activity tagged to this specific code. The two recent opportunities in the dataset are unrelated to fomivirsen: one records a completed piggyback pharmaceutical warehouse award by the Illinois Department of Public Health for doxycycline and ciprofloxacin tablets, and the other captures a Seminole County, Florida procurement for naloxone and drug deactivation systems. Neither solicitation involves fomivirsen or the antiviral drug class the code describes. The mismatch suggests either inconsistent code assignment in the source data or that this commodity sees minimal state and local contracting activity under its designated UNSPSC classification.

No open solicitations for fomivirsen appear in the recent-opportunities block. The Illinois award of $2,999,999.11 over three years to Chartwell Rx LLC and the Seminole County IFB for naloxone (due date July 26, 2023, now closed) represent completed transactions in tangential pharmaceutical categories, not active markets for the specific drug this code designates. Activity under UNSPSC 51342602 itself does not support a pursue recommendation at this time.